October is Gaucher Awareness Month, which is an important time to raise awareness and provide help to people living with this life-altering condition. Pfizer is excited to announce that it is launching the Gaucher Personal Support (GPS) Mentor Connect program, a new resource for people living with Gaucher disease. This program will provide one-on-one support and an opportunity to speak to someone who understands what it’s like to live with this condition.

“Pfizer is proud to bring the Gaucher Personal Support (GPS) Mentor Connect program to the Gaucher community,” said Mariah Kelly, RN, Patient Affairs Liaison, Pfizer. “We are committed to improving the lives of patients with Gaucher disease and believe this program can provide support to people who are looking to share their journey and learn from the experiences of others.”

GPS Mentor Connect is a private, one-on-one, over the phone support program that provides patients the opportunity to connect with GPS Ambassadors who are adults living with Type 1 Gaucher disease. Patients can confidentially discuss a wide range of topics, from experience with Gaucher disease to insurance/reimbursement challenges to daily struggles and successes, with a GPS Ambassador. No matter where a patient may be, he or she is only a phone call away from being connected with an Ambassador.

“As someone living with Gaucher disease, I believe having someone to share your story with is essential,” said GPS Ambassador Kim R. “By connecting with others to discuss their insights and experiences, people living with Gaucher disease can learn from one another and their shared journey. It’s important for Gaucher patients to know that they’re not alone.”

Visit www.GaucherMentorConnect.com to learn more about Gaucher disease and a treatment option made in Israel from Pfizer. Information about Pfizer’s GPS program is also available online or by calling 1- 855-353-5976.

ELELYSO™ (taliglucerase alfa) for injection is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for adults with a confirmed diagnosis of Type 1 Gaucher disease.

As with any intravenous protein medicine, like enzyme replacement therapy (ERT), severe allergic reactions (including anaphylaxis) have been observed in patients treated with ELELYSO. If this occurs, ELELYSO should be immediately discontinued, and appropriate medical treatment should be initiated. Patients who have experienced anaphylaxis to ELELYSO or another ERT should proceed with caution upon retreatment.

In addition, infusion reactions (including allergic reactions)—defined as a reaction occurring within 24 hours of the infusion—were the most commonly observed reactions to ELELYSO. The most commonly observed infusion reactions were headache, chest pain or discomfort, weakness, fatigue, hives, abnormal redness of the skin, increased blood pressure, back or joint pain, and flushing. Other infusion or allergic reactions included swelling of the face, mouth, and/or throat; wheezing; shortness of breath; skin color turning blue; coughing; and low blood pressure. Most of these reactions were mild and did not require treatment.

Management of infusion reactions is based on the type and severity of the reaction. Your doctor may manage infusion reactions by temporarily stopping the infusion, slowing the infusion rate, or treating with medications such as an antihistamine and/or a fever reducer. Treatment with antihistamines and/or corticosteroids prior to infusion with ELELYSO may prevent these reactions.

Please see ELELYSO full Prescribing Information here.

As with all therapeutic proteins, including ERTs, there is a possibility of developing antibodies to ELELYSO (taliglucerase alfa). However, it is currently unclear whether this has an impact on the clinical response or adverse reactions. Patients with an immune response to other ERTs who are switching to ELELYSO should continue to be monitored for antibodies. Comparison of the frequency of antibodies across ERTs may be misleading. Patients who have developed infusion or immune reactions with ELELYSO or with another ERT should be monitored for antidrug antibodies when being treated with ELELYSO.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

# # #